This Chinese firm in the Medical - Services group is enduring distributional pressure this week after challenging its 52-week high with a recent spurt of volume-driven gains. Little resistance remains due to overhead supply. It reported a loss of 11 cents per share on +44% sales revenues for the Mar '15 quarter. Prior mid-day reports noted - "Due to report earnings on June 8th. In the 3 latest quarterly comparisons through Dec '14 it showed strong sales revenues and earnings increases above the +25% minimum guideline (C criteria). Limited history is a concern, while it made a choppy ascent from its $14 IPO on 4/09/14."
This Chinese firm in the Medical - Services group is pulling back this week after challenging its 52-week high with a recent spurt of volume-driven gains. Little resistance remains due to overhead supply. Prior mid-day reports noted - "Due to report earnings on June 8th. In the 3 latest quarterly comparisons through Dec '14 it showed strong sales revenues and earnings increases above the +25% minimum guideline (C criteria). Limited history is a concern, while it made a choppy ascent from its $14 IPO on 4/09/14."
This Chinese firm in the Medical - Services group has been challenging its 52-week high with a recent spurt of volume-driven gains and no resistance remains. Prior mid-day reports noted - "Due to report earnings on June 8th. In the 3 latest quarterly comparisons through Dec '14 it showed strong sales revenues and earnings increases above the +25% minimum guideline (C criteria). Limited history is a concern, while it made a choppy ascent from its $14 IPO on 4/09/14."
This Chinese firm in the Medical - Services group is pulling back today after challenging its 52-week high with the prior session's 7th consecutive volume-driven gain. The 6/01/15 mid-day report noted - "Due to report earnings on June 8th. In the 3 latest quarterly comparisons through Dec '14 it showed strong sales revenues and earnings increases above the +25% minimum guideline (C criteria). Limited history is a concern, while it made a choppy ascent from its $14 IPO on 4/09/14."
This Chinese firm in the Medical - Services group is perched near its 52-week high with today's 7th consecutive volume-driven gain. Due to report earnings on June 8th. In the 3 latest quarterly comparisons through Dec '14 it showed strong sales revenues and earnings increases above the +25% minimum guideline (C criteria). Limited history is a concern, while it made a choppy ascent from its $14 IPO on 4/09/14.